New Cancer Vaccine Shows Promising Results in Patients

A recent study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center has reported promising results from a new cancer vaccine, ELI-002 2P, aimed at treating patients with pancreatic and colorectal cancer. These two types of cancer are known for their aggressive nature and challenging treatment landscapes. The vaccine targets KRAS mutations, which are prevalent in many solid tumors and drive a significant portion of pancreatic (90%) and colorectal (50%) cancers. In a trial involving 25 patients, the vaccine demonstrated the ability to elicit durable T-cell responses, with 84% of participants developing KRAS-specific T cells. The findings, published in Nature Medicine on November 10, 2026, indicate a median relapse-free survival of 16.33 months and an overall survival of 28.94 months, both of which surpass historical benchmarks for these cancers.

The historical context of this research highlights the difficulties in treating KRAS-driven cancers. KRAS mutations have long posed one of the toughest challenges in cancer therapy, with traditional treatments often falling short. The ELI-002 2P vaccine represents a novel approach by utilizing a standardized, off-the-shelf solution that does not require personalization for each patient. This method contrasts with other cancer therapies that frequently necessitate individualized treatments based on specific patient mutations. By focusing on KRAS mutations, the vaccine aims to train the immune system to recognize and combat cancer cells effectively, which is crucial for improving outcomes for patients with high-risk cancer profiles.

Implementation of the ELI-002 2P vaccine involved a trial that included 25 patients who had previously undergone surgery for pancreatic ductal adenocarcinoma or colorectal cancer. These patients exhibited signs of minimal residual disease, indicated by traces of cancer DNA in their blood. Each participant received a series of vaccinations specifically designed to stimulate immune responses targeting KRAS mutations. The trial employed advanced amphiphile technology developed by Elicio Therapeutics, allowing antigens to be delivered directly to the lymph nodes, where immune responses are activated. Remarkably, 84% of the patients generated KRAS-specific T cells, and a significant portion of these immune cells persisted over time, providing a strong defense against potential cancer recurrence.

The broader economic, environmental, and social benefits of this research are substantial. With pancreatic and colorectal cancers being among the leading causes of cancer-related mortality, successful treatments can significantly alleviate the burden on healthcare systems and improve quality of life for patients. The findings suggest that not only does the ELI-002 2P vaccine enhance immune responses against KRAS mutations, but it also demonstrates potential for broader anti-tumor activity, as 67% of tested patients developed responses to additional tumor-associated mutations. This could pave the way for more effective, less personalized treatment strategies that are both cost-effective and accessible to a larger patient population.

Looking toward the future, the research team has already completed enrollment for a larger Phase 2 study of a next-generation version of the vaccine, ELI-002 7P, which targets a broader array of KRAS mutations. This advancement underscores the ongoing commitment to improving cancer treatment options and building on the promising results observed in the initial trial. The study’s senior authors, Dr. Shubham Pant from the MD Anderson Cancer Center and Dr. Eileen O’Reilly from Memorial Sloan Kettering Cancer Center, are optimistic about the potential implications of this research for global cancer therapy. With continued investigation and development, the ELI-002 vaccine could represent a significant step forward in the fight against some of the most challenging cancers.